Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria

European Journal of Medicinal Chemistry
2018.0

Abstract

Even though many GyrB and ParE inhibitors have been reported in the literature, few possess activity against Gram-negative bacteria. This is primarily due to limited permeability across Gram-negative bacterial membrane as well as bacterial efflux mechanisms. Permeability of compounds across Gram-negative bacterial membranes depends on many factors including physicochemical properties of the inhibitors. Herein, we show the optimization of pyridylureas leading to compounds with potent activity against Gram-negative bacterial species such as P.aeruginosa, E.coli and A.baumannii.

Knowledge Graph

Similar Paper

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria
European Journal of Medicinal Chemistry 2018.0
Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens
Journal of Medicinal Chemistry 2021.0
New N -phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity
European Journal of Medicinal Chemistry 2018.0
Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria
Journal of Medicinal Chemistry 2017.0
Fragment-to-Hit-to-Lead Discovery of a Novel Pyridylurea Scaffold of ATP Competitive Dual Targeting Type II Topoisomerase Inhibiting Antibacterial Agents
Journal of Medicinal Chemistry 2013.0
DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity
Bioorganic & Medicinal Chemistry Letters 2009.0
An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors
European Journal of Medicinal Chemistry 2019.0
New N-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors
MedChemComm 2019.0
5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV
Bioorganic & Medicinal Chemistry Letters 2009.0
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
ACS Medicinal Chemistry Letters 2016.0